Company: NCEL
Filing Date: 2025-06-16
Form Type: 425
Source: 0001213900-25-054487
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-06-16
Form: 425
Chunk 3
---
                    
 toward late-stage development (e.g., narcolepsy, neurodegeneration). |

Our anticipated merger with Kadimastem is expected
to mark a transformational pivot—uniting our proprietary DOXA platform and the cell-therapy assets under one roof. With a fortified
capital structure, and a unified board guiding our research and development direction, we are strategically positioned for meaningful
value creation.

In Conclusion

Thanks to your trust and resilience, NLS stands
on the edge of a powerful new chapter. We anticipate the closing of the merger to occur in the near future, followed by an energized integration
phase and accelerated clinical momentum.

Thank you for your enduring support. Together,
we will accelerate development, diversify our pipeline, and enhance long-term shareholder value.

With optimism,

Alexander C. Zwyer

Chief Executive Officer

NLS Pharmaceutics (NASDAQ: NLSP)

<div align='center'>2</div>

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical
company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development
of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered
in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing
product candidates. For more information, please visit www.nlspharma.com.

About Kadimastem

Kadimastem is a clinical stage cell therapy company,
developing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation
of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy
in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes.
IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially
cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem
and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention
and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded